Avance Clinical Highlights Oncology Expertise at ASCO 2026
CHICAGO, Ill., June 20, 2026 Avance Clinical, a leading global Contract Research Organization (CRO) specializing in accelerating clinical development...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
CHICAGO, Ill., June 20, 2026 Avance Clinical, a leading global Contract Research Organization (CRO) specializing in accelerating clinical development...
PARSIPPANY, N.J. and TEL AVIV, Israel, June 20, 2026 Teva Pharmaceutical Industries Ltd. has unveiled compelling new long-term data...
COPENHAGEN, Denmark, June 18, 2026 Allarity Therapeutics, Inc. announced the presentation of a Trial-in-Progress poster for its ongoing Phase...
BOSTON, MA, June 18, 2026 Curiumâ„¢ has secured a significant legal and commercial milestone after prevailing in a patent...
LANSING, Mich. and BOSTON, Mass., June 16, 2026 Niowave, Inc. and Ratio Therapeutics Inc. have entered into a strategic...
TUCSON, Arizona, USA, June 11, 2026 Roche Diagnostics has announced a significant expansion of its precision oncology diagnostics portfolio...
SHANGHAI, China & CAMBRIDGE, Massachusetts, USA – June 9, 2026 Zai Lab has received approval from China’s National Medical...
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...
CRANFORD, N.J., June 1, 2026 Citius Oncology has announced encouraging Phase 1 clinical findings evaluating LYMPHIR® (denileukin diftitox-cxdl) in...
